Last reviewed · How we verify
NCT05149157: SCRIPT
Trajectories and Mechanisms of Recovery From Malaria: An Observational Study
trial testing Symptomatic malaria in Malaria in 240 participants. Participants enrolled and being followed up; not accepting new ones.
5 January 2026
Quick facts
| Lead sponsor | Imperial College London |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 240 |
| Start date | 2 August 2022 |
| Primary completion | 5 January 2026 |
| Estimated completion | 5 January 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Symptomatic malaria
Conditions studied
- Malaria — all drugs for Malaria →
Sponsor
Imperial College London
Who can join
8 Days and older, any sex, with Malaria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational research study aims to answer the question: 'Which aspects of human biology play an important role in recovery from symptomatic malaria?' In particular, the researchers aim to identify human genes for which the level of gene activity reflects the patient's overall rate of recovery. The researchers believe this approach may reveal new targets for adjunctive therapies. The researchers aim to recruit 240 people, of all ages, who have been diagnosed with symptomatic malaria at selected hospitals in London. Blood samples, urine samples, and clinical information will be collected over the 14 days following malaria diagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05149157
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Malaria
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07036159 — A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months · Phase 2 · recruiting
- NCT06735209 — First-in-Human PfSPZ-LARC2 Vaccination/CHMI · Phase 1 · active not recruiting
- NCT06854042 — A Study of Oral E1018 in Healthy Adult Participants · Phase 1 · recruiting
- NCT06607003 — Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha · Phase 1 · recruiting
Other Imperial College London trials
Trials by the same sponsor.
- NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
- NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
- NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
- NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
- NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05149157 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imperial College London
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05149157.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing